2018
PAGE 2018, Montreux, Switzerland
A semi-mechanistic model of targeted therapy for melanoma
Authors: Dmitrii Shchelokov, Oleg Demin Jr
Simulations of tau-targeted therapies using quantitative systems pharmacology model of tau pathology
Authors: Tatiana Karelina, Alexander Stepanov, Oleg Demin
Modeling of amyloid accumulation in subjects at risk of Alzheimer’s disease under BACE inhibition treatment
Authors: Etienne Pigeolet1, Konstantinos Biliouris2, Ulf Neumann3, Alexandra Urusova4, Oleg Demin4, Tatiana Karelina4
Affiliation: 1Novartis Pharma AG, Basel, Switzerland; 2Novartis Institute for Biomedical Research, Cambridge, USA; 3Novartis Institute for Biomedical Research, Basel, Switzerland; 4InSysBio, Moscow, Russia
AAT-AD/PD Focus Meeting, Torino, Italy
In silico implementation of tauopathy transgenic mouse model
Speaker: Alexander Stepanov
ASCPT 2018, Orlando, FL, USA
PBPK modeling for therapeutic nanoparticles loaded with drug: distribution and release
Authors: Evgeny Metelkin, Oleg Demin
Translational QSP model of amyloid beta allows to predict both short and long term response of AD patients to different therapies
Authors: Tatiana Karelina1, Oleg Demin1, Oleg Demin Jr1, Timothy Nicholas2
Affiliation: 1InSysBio, Moscow, Russia; 2Pfizer Worldwide R&D, Groton, CT, USA
Multiple myeloma quantitative systems pharmacology model: development and usage for pomalidomide influence evaluation
Authors: Svetlana Rubina, Oleg Demin, Oleg Demin Jr
2017
ACoP8, Fort Lauderdale, FL, US
Mechanistic model for the role of the microgliall cells in amyloid accumulation and its modulation by immunotherapy
Authors: Tatiana Karelina1, Alexander Stepanov1, Theresa Yuraszeck2, Dean Hickman2, Steve Wood2
Affiliation: 1InSysBio, Moscow, Russia; 2Amgen Inc., Thousand Oaks, CA, USA
Tau propagation system pharmacology model based on three-component memory-retrieval system predicts heterogeneous response to immunotherapy in brain regions
Authors: Tatiana Karelina1, Alexander Stepanov1, Timothy Nicholas2
Affiliation: 1InSysBio, Moscow, Russia; 2Pfizer Worldwide R&D, Groton, CT, USA
A Quantitative Systems Pharmacology Model of Asthma
Authors: Sergey Smirnov1, Galina Lebedeva1, Oleg Demin1, Tatiana Petukhova1, Lourdes Cucurull-Sanchez2, David Fairman2
Affiliation: 1InSysBio, Moscow, Russia; 2GSK Medicines Research Centre, Stevenage, UK
Model-based analysis of clinical assays for assessing the efficacy of vaccines against Respiratory Syncytial Virus (RSV)
Authors: Galina Lebedeva, Nikolai Pakhomov, Oleg Demin, Oleg Demin Jr
Evaluation of Potential Low-Dose Regimens of Oral Fixed-Dose Combination of Cytidine Deaminase Inhibitor E7727 with Decitabine (ASTX727-LD) to Minimize Decitabine-Mediated Neutropenia in Low-Risk MDS Subjects Using Systems Pharmacology Modeling
Authors: Antonina Nikitich1, Oleg Demin1, Oleg Demin Jr1, Aram Oganesian2
Affiliation: 1InSysBio, Moscow, Russia; 2Astex Pharmaceuticals Inc., Pleasanton, CA
7th German-Russian Week of the Young Researcher, Moscow, Russia
SbmlViewer is a visualization tool for systems biology modeling
Authors: Viktoria Tkachenko, Evgeny Metelkin
AD/PD 2017, Vienna, Austria
Amyloid toxicity and different mechanisms of action for amyloid-targeted treatments studied by quantitative systems pharmacology model
Authors: Tatiana Karelina1, Timothy Nicholas2
Affiliation: 1InSysBio, Moscow, Russia; 2Pfizer Worldwide R&D, Groton, CT, USA
First
Prev